Cardiac stereotactic ablative radiotherapy for control of refractory ventricular tachycardia: initial UK multicentre experience.
Open Heart
; 8(2)2021 11.
Article
in En
| MEDLINE
| ID: mdl-34815300
ABSTRACT
BACKGROUND:
Options for patients with ventricular tachycardia (VT) refractory to antiarrhythmic drugs and/or catheter ablation remain limited. Stereotactic radiotherapy has been described as a novel treatment option.METHODS:
Seven patients with recurrent refractory VT, deemed high risk for either first time or redo invasive catheter ablation, were treated across three UK centres with non-invasive cardiac stereotactic ablative radiotherapy (SABR). Prior catheter ablation data and non-invasive mapping were combined with cross-sectional imaging to generate radiotherapy plans with aim to deliver a single 25 Gy treatment. Shared planning and treatment guidelines and prospective peer review were used.RESULTS:
Acute suppression of VT was seen in all seven patients. For five patients with at least 6 months follow-up, overall reduction in VT burden was 85%. No high-grade radiotherapy treatment-related side effects were documented. Three deaths (two early, one late) occurred due to heart failure.CONCLUSIONS:
Cardiac SABR showed reasonable VT suppression in a high-risk population where conventional treatment had failed.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Tachycardia, Ventricular
/
Catheter Ablation
/
Heart Rate
Type of study:
Etiology_studies
/
Guideline
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
En
Journal:
Open Heart
Year:
2021
Type:
Article
Affiliation country:
United kingdom